pioglitazone has been researched along with Glaucoma in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone is an agonist of the peroxisome proliferator-activated receptor gamma (PPARĪ³) whose pleiotrophic activities include modulation of cellular energy metabolism and reduction in inflammation." | 5.72 | Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models. ( Dumitrescu, AV; Elwood, BW; Gramlich, OW; Kuehn, MH; Wadkins, D; Zeng, H, 2022) |
| "Pioglitazone is an agonist of the peroxisome proliferator-activated receptor gamma (PPARĪ³) whose pleiotrophic activities include modulation of cellular energy metabolism and reduction in inflammation." | 1.72 | Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models. ( Dumitrescu, AV; Elwood, BW; Gramlich, OW; Kuehn, MH; Wadkins, D; Zeng, H, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zeng, H | 1 |
| Dumitrescu, AV | 1 |
| Wadkins, D | 1 |
| Elwood, BW | 1 |
| Gramlich, OW | 1 |
| Kuehn, MH | 1 |
1 other study available for pioglitazone and Glaucoma
| Article | Year |
|---|---|
Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models.
Topics: Animals; Glaucoma; Humans; Intraocular Pressure; Mice; Mice, Inbred C57BL; Pioglitazone; Retinal Gan | 2022 |